- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Path Towards a Tailored Clinical Biosimilar Development ; volume:34 ; number:3 ; day:7 ; month:4 ; year:2020 ; pages:297-306 ; date:6.2020
BioDrugs ; 34, Heft 3 (7.4.2020), 297-306, 6.2020
- Urheber
-
Schiestl, Martin
Ranganna, Gopinath
Watson, Keith
Jung, Byoungin
Roth, Karsten
Capsius, Björn
Trieb, Michael
Bias, Peter
Maréchal-Jamil, Julie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-020-00422-1
- URN
-
urn:nbn:de:101:1-2020071622132042769621
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schiestl, Martin
- Ranganna, Gopinath
- Watson, Keith
- Jung, Byoungin
- Roth, Karsten
- Capsius, Björn
- Trieb, Michael
- Bias, Peter
- Maréchal-Jamil, Julie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm
MYL-1402O: A Bevacizumab Biosimilar
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm
MYL-1402O: A Bevacizumab Biosimilar
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm